Pregnancy: Doxorubicin hydrochloride is suspected to cause serious birth defects when administered during pregnancy. Therefore, Doxorubicin should not be used during pregnancy unless clearly necessary.
Women of child-bearing potential: Women of child-bearing potential must be advised to avoid pregnancy while they or their male partner are receiving Doxorubicin and in the six months following discontinuation of Doxorubicin therapy.
Breast-feeding: It is not known whether Doxorubicin is excreted in human milk. Because many medicinal products, including anthracyclines, are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants, therefore mothers must discontinue nursing prior to beginning Doxorubicin treatment. Health experts recommend that HIV infected women do not breast-feed their infants under any circumstances in order to avoid transmission of HIV.
Fertility: The effect of doxorubicin hydrochloride on human fertility has not been evaluated.